Metabolic sequelae associated with androgen deprivation therapy for prostate cancer

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Current Opinion in Endocrinology, Diabetes & Obesity

• Publication date

  2010-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/MED.0b013e3283391fd1PMID 20404727PMCID PMC5120548
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Androgen Deprivation Therapy for Prostate Cancer

  2011cited by this paper
• Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.

  2010cited by this paper
• Major Lipids, Apolipoproteins, and Risk of Vascular Disease

  2010cited by this paper
• Metabolic complications of androgen deprivation therapy for prostate cancer.

  2009cited by this paper
• Low serum testosterone and estradiol predict mortality in elderly men.

  2009cited by this paper
• Impact of androgen deprivation therapy on cardiovascular disease and diabetes.

  2009cited by this paper
• Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31.

  2009cited by this paper
• Effect of testosterone replacement therapy on arterial stiffness in older hypogonadal men.

  2009cited by this paper
• Major lipids, apolipoproteins, and risk of vascular disease.

  2009cited by this paper
• Prostate Cancer Survivorship: Prevention and Treatment of the Adverse Effects of Androgen Deprivation Therapy

  2009cited by this paper
• Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.

  2008cited by this paper
• Introduction The Aging Male

  2008cited by this paper
• The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance.

  2008cited by this paper
• Low serum testosterone and mortality in older men.

  2008cited by this paper
• Metabolic changes during gonadotropin‐releasing hormone agonist therapy for prostate cancer

  2008cited by this paper
• Metabolic and cardiovascular effects of androgen deprivation therapy

  2008cited by this paper
• Sarcopenic obesity: definition, cause and consequences

  2008cited by this paper
• The Dark Side of Testosterone Deficiency: II. Type 2 Diabetes & Insulin Resistance Short Running Title: Testosterone deficiency, Insulin Resistance & Type 2 Diabetes

  2008cited by this paper
• Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.

  2008cited by this paper
• Nonfasting triglycerides and risk of ischemic stroke in the general population.

  2008cited by this paper
• Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths.

  2007cited by this paper
• Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions.

  2007cited by this paper
• Triglycerides and the Risk of Coronary Heart Disease: 10 158 Incident Cases Among 262 525 Participants in 29 Western Prospective Studies

  2007cited by this paper
• Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.

  2007cited by this paper
• Abdominal Visceral and Subcutaneous Adipose Tissue Compartments: Association With Metabolic Risk Factors in the Framingham Heart Study

  2007cited by this paper
• Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer

  2007cited by this paper
• Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer.

  2007cited by this paper
• Sex steroids and all-cause and cause-specific mortality in men.

  2007cited by this paper
• The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease.

  2006cited by this paper
• Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer.

  2006cited by this paper
• Insulin sensitivity during combined androgen blockade for prostate cancer.

  2006cited by this paper
• Metabolic syndrome and early-onset coronary artery disease: is the whole greater than its parts?

  2006cited by this paper
• Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes.

  2006cited by this paper
• Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.

  2006cited by this paper
• The rising prevalence of androgen deprivation among older American men since the advent of prostate‐specific antigen testing: a population‐based cohort study

  2006cited by this paper
• Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.

  2006cited by this paper
• Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891.

  2006cited by this paper
• Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men.

  2006cited by this paper
• Effect of androgen suppression on hemoglobin in prostate cancer patients undergoing salvage radiotherapy plus 2-year buserelin acetate for rising PSA after surgery.

  2005cited by this paper
• Increasing use of gonadotropin‐releasing hormone agonists for the treatment of localized prostate carcinoma

  2005cited by this paper
• Endogenous sex hormones and metabolic syndrome in aging men.

  2005cited by this paper
• Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men.

  2005cited by this paper
• Risk of fracture after androgen deprivation for prostate cancer.

  2005cited by this paper
• The metabolic syndrome: time for a critical appraisal

  2005cited by this paper
• Risk of fracture after androgen deprivation for prostate cancer.

  2005cited by this paper
• Cortisol, Testosterone, and Coronary Heart Disease: Prospective Evidence From the Caerphilly Study

  2005cited by this paper
• The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.

  2005cited by this paper
• Changes in bone mineral density and body composition during initial and long‐term gonadotropin‐releasing hormone agonist treatment for prostate carcinoma

  2005cited by this paper
• Androgen deprivation therapy for prostate cancer.

  2005cited by this paper
• Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer.

  2005cited by this paper
• The metabolic syndrome: requiescat in pace.

  2005cited by this paper
• How are hemoglobin levels affected by androgen deprivation in non-metastatic prostate cancer patients?

  2005cited by this paper
• The changing face of low-risk prostate cancer: trends in clinical presentation and primary management.

  2004cited by this paper
• 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.

  2004cited by this paper
• Changing patterns in competing causes of death in men with prostate cancer: a population based study.

  2004cited by this paper
• Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer.

  2004cited by this paper
• Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia.

  2003cited by this paper
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

  2002cited by this paper
• Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma

  2002cited by this paper
• Changes in body composition during androgen deprivation therapy for prostate cancer.

  2002cited by this paper
• The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men.

  2002cited by this paper
• Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy.

  2002cited by this paper
• Long‐term effects of androgen deprivation therapy in prostate cancer patients

  2002cited by this paper
• Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms.

  2001cited by this paper
• The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer.

  2001cited by this paper
• Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms.

  2000cited by this paper
• Body Composition in Healthy Aging

  2000cited by this paper
• Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer.

  2000cited by this paper
• Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort.

  2000cited by this paper
• Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts Male Aging Study

  2000cited by this paper
• Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer.

  1999cited by this paper
• Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age.

  1999cited by this paper
• Testosterone, body composition and aging.

  1999cited by this paper
• Cause of death in men diagnosed with prostate carcinoma

  1998cited by this paper
• Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study.

  1998cited by this paper
• Hyperinsulinemia and the risk of stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study.

  1998cited by this paper
• Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31.

  1997cited by this paper
• Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group.

  1997cited by this paper
• Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group.

  1997cited by this paper
• Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade.

  1997cited by this paper
• Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.

  1997cited by this paper
• Testosterone replacement increases fat-free mass and muscle size in hypogonadal men.

  1997cited by this paper
• Development of anemia and recovery in prostate cancer patients treated with combined androgen blockade and radiotherapy

  1996cited by this paper
• Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism.

  1996cited by this paper
• Hyperinsulinemia as an independent risk factor for ischemic heart disease.

  1996cited by this paper
• Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia.

  1995cited by this paper
• Effects of the nonsteroidal antiandrogen Casodex on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia.

  1995cited by this paper
• Androgen treatment of middle-aged, obese men: effects on metabolism, muscle and adipose tissues.

  1992cited by this paper
• Nutritional and metabolic effects of gonadotropin-releasing hormone agonist treatment for prostate cancer.

  1990cited by this paper
• Leuprolide versus diethylstilbestrol for previously untreated stage D2 prostate cancer. Results of a prospectively randomized trial.

  1986cited by this paper
• Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).

  1986cited by this paper
• Leuprolide versus diethylstilbestrol for previously untreated stage D2 prostate cancer: Results of a prospectively randomized trial

  1986cited by this paper
• Leuprolide versus diethylstilbestrol for metastatic prostate cancer.

  1984cited by this paper
• Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1998 by The Endocrine Society Testosterone Deficiency in Young Men: Marked Alterations in Whole Body Protein Kinetics, Strength, and Adiposity*

  year unknowncited by this paper

• Metabolomic Insights Into Saliva as a Non-Invasive Surrogate for Serum to Enable Community-Based Biomarker Investigation.

  2026cites this paper
• GLP1 Receptor Agonism Alters Growth and Therapeutic Response in Prostate Cancer.

  2025cites this paper
• Effects of GnRH agonists and antagonists on cardiovascular and metabolic systems in adults: Mechanistic pathways and risk management.

  2025cites this paper
• Cardiovascular effects of hormone therapy in prostate and breast cancer: a contemporary review

  2025cites this paper
• Bridging Cancer and Cardiovascular Health: A Comprehensive Review of Cardiotoxicity in Modern Oncology

  2025cites this paper
• May Patients Receiving GLP-1 Agonists Be at Lower Risk of Prostate Cancer Aggressiveness and Progression?

  2025cites this paper
• Cardiovascular Risk Assessment in Prostate Cancer: The Role of Coronary Artery Calcium Scoring.

  2025cites this paper
• Current Clinical Aspects of Androgen Deprivation Therapy for Locally Advanced and Metastatic Prostate Cancer: A Scoping Review for Urologists and Medical Providers

  2024cites this paper
• Novel Therapeutic Targets on the Horizon: An Analysis of Clinical Trials on Therapies for Bone Metastasis in Prostate Cancer

  2024cites this paper
• Adverse metabolic consequences of androgen deprivation therapy (ADT) on Asian patients with prostate cancer: Primary results from the real‐life experience of ADT in Asia (READT) study

  2023cites this paper
• Home-based versus supervised group exercise in men with prostate cancer on androgen deprivation therapy: A randomized controlled trial and economic analysis.

  2023cites this paper
• Impact of Androgen Deprivation Therapy on Cardiovascular Outcomes in Prostate Cancer

  2022influential citation
• Relationship between Androgen Deprivation Therapy and Abdominal Adipose Tissue

  2022cites this paper
• Hyperpolarised 13C-MRI identifies the emergence of a glycolytic cell population within intermediate-risk human prostate cancer

  2022cites this paper
• Personalized Medicine for Prostate Cancer: Is Targeting Metabolism a Reality?

  2022cites this paper
• Association between atherogenic lipids and GnRH agonists for prostate cancer in men with T2DM: a nationwide, population-based cohort study in Sweden

  2022cites this paper
• Risks of metabolic diseases and androgen deprivation therapy for prostate cancer in a Chinese population: a prospective multi-centre cohort study

  2022cites this paper
• The Influence of Anti-Diabetic Drugs on Prostate Cancer

  2021cites this paper
• Low Carbohydrate Diets in Cancer Therapeutics: Current Evidence

  2021cites this paper
• PCK1 regulates neuroendocrine differentiation in a positive feedback loop of LIF/ZBTB46 signalling in castration-resistant prostate cancer

  2021cites this paper
• Severe acute respiratory syndrome coronavirus 2 infection in patients with prostate cancer: A critical review

  2021cites this paper
• Myokine Expression and Tumor-Suppressive Effect of Serum after 12 wk of Exercise in Prostate Cancer Patients on ADT

  2021cites this paper
• The effect of medical and urologic disorders on the survival of patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide

  2021cites this paper
• Barriers and facilitators related to undertaking physical activities among men with prostate cancer: a scoping review

  2021cites this paper
• Metabolomics in cancer research and emerging applications in clinical oncology

  2021cites this paper
• Leptin antagonism inhibits prostate cancer xenograft growth and progression.

  2021cites this paper
• Endocrinology of the Aging Prostate: Current Concepts

  2021cites this paper
• Pharmacoepidemiological Evaluation in Prostate Cancer—Common Pitfalls and How to Avoid Them

  2021cites this paper
• EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer.

  2020cites this paper
• The Adverse Effects of Androgen Deprivation Therapy in Prostate Cancer and the Benefits and Potential Anti-oncogenic Mechanisms of Progressive Resistance Training

  2020cites this paper
• Cardiovascular Complications of Prostate Cancer Treatment

  2020cites this paper
• Urologic Endocrinology

  2020cites this paper
• Optimizing screening and management of cardiovascular health in prostate cancer.

  2020cites this paper
• Insulin Enhances Migration and Invasion in Prostate Cancer Cells by Up-Regulation of FOXC2

  2019cites this paper
• The evolving role of diet in prostate cancer risk and progression

  2019cites this paper
• Emerging role of testosterone in pancreatic β-cell function and insulin secretion.

  2019cites this paper
• Androgen deprivation therapy promotes an obesity-like microenvironment in periprostatic fat

  2019cites this paper
• Aging Men and Prostate Cancer

  2018cites this paper
• Risks of Major Long‐Term Side Effects Associated with Androgen‐Deprivation Therapy in Men with Prostate Cancer

  2018cites this paper
• Cardiovascular and Metabolic Effects of Androgen-Deprivation Therapy for Prostate Cancer.

  2018cites this paper
• Hepatic actions of androgens in the regulation of metabolism

  2018cites this paper
• CANCER AND DIABETES

  2017cites this paper
• EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.

  2017cites this paper
• The Associations between Serum total Testosterone Levels, Anthropometric Measurements and Metabolic Parameters in Elderly and Young Male Patients with Type 2 Diabetes Mellitus in Taiwan

  2017cites this paper
• The Role of Hormonal Treatment in Prostate Cancer

  2017cites this paper
• Evaluation of a multidisciplinary allied health prostate cancer clinic

  2017cites this paper
• Adult-Onset Hypogonadism.

  2016cites this paper
• Aging Men and Prostate Cancer

  2016cites this paper
• The metabolic syndrome and ED

  2016cites this paper
• Androgen-deprivation therapy and pancreatic β-cell dysfunction in men.

  2016cites this paper
• Role of free testosterone levels in patients with metastatic castration-resistant prostate cancer receiving second-line therapy

  2016cites this paper
• Klinefelter Syndrome and Metabolic Disorder

  2016cites this paper
• Quantifying the Evidence for the Risk of Metabolic Syndrome and Its Components following Androgen Deprivation Therapy for Prostate Cancer: A Meta-Analysis

  2015cites this paper
• Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer

  2015cites this paper
• Testosterone and obesity

  2015influential citation
• Metabolic syndrome in castration‐resistant prostate cancer patients treated with abiraterone

  2015cites this paper
• Re: The Effect of Testicular Cryoablation on Testosterone Level in Rats: An Experimental Model of Histopathological Orchiectomy.

  2015cites this paper
• Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer.

  2015cites this paper
• EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

  2014cites this paper
• Erectile dysfunction in primary care: a focus on cardiometabolic risk evaluation and stratification for future cardiovascular events.

  2014cites this paper
• The effect of testosterone on factors associated with diabetes, atherosclerosis and obesity.

  2014cites this paper
• Androgen Receptor Roles in Insulin Resistance and Obesity in Males: The Linkage of Androgen-Deprivation Therapy to Metabolic Syndrome

  2014cites this paper
• Physical functioning for prostate health.

  2014cites this paper
• The Metabolic Investigation of Erectile Dysfunction: Cardiometabolic Risk Stratification

  2014cites this paper
• Underutilization of local salvage therapy after radiation therapy for prostate cancer.

  2014cites this paper
• Effect of androgen deprivation therapy on cardiovascular risk factors in prostate cancer

  2013cites this paper
• Endurance training improves insulin sensitivity and body composition in prostate cancer patients treated with androgen deprivation therapy.

  2013cites this paper
• MODULATION OF SEXUAL AND SLEEP FUNCTIONS BY ESTROGEN IN CASTRATED MALE RATS AS A MODEL FOR PROSTATE CANCER PATIENTS ON ANDROGEN DEPRIVATION THERAPY

  2013cites this paper
• Patients and partners lack knowledge of androgen deprivation therapy side effects.

  2013cites this paper
• The effect of estrogen on the sexual interest of castrated males: Implications to prostate cancer patients on androgen-deprivation therapy.

  2013cites this paper
• Testosterone: a metabolic hormone in health and disease.

  2013cites this paper
• Metabolic syndrome as a peculiar target for management of prostate cancer patients.

  2013cites this paper
• The influence of obesity in patients with prostate cancer - Review of the literature

  2013cites this paper
• Management of Prostate Cancer: EAU Guidelines on Screening, Diagnosis and Treatment

  2012cites this paper
• Words of wisdom. Re: Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.

  2012cites this paper
• Words of wisdom. Re: Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.

  2012cites this paper
• The Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate Cancer

  2012cites this paper
• Current world literature.

  2012cites this paper
• Testosterone: List of Contributors

  2012cites this paper
• Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.

  2011cites this paper
• Cells Steroidogenesis in Prostate Cancer

  2011cites this paper
• Supplement Article Traditional Approaches to Androgen Deprivation Therapy

  2011cites this paper
• EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

  2011cites this paper
• ADT and the metabolic syndrome: no good deed goes unpunished.

  2011cites this paper
• Traditional approaches to androgen deprivation therapy.

  2011cites this paper
• Changes in blood glucose and cholesterol levels due to androgen deprivation therapy in men with non-metastatic prostate cancer.

  2011cites this paper
• Don’t think once, think twice! the cardiovascular effects of androgen deprivation therapy

  2011cites this paper
• The role of insulin and IGF2 signalling on metabolic pathways in prostate cancer progression

  2011cites this paper
• Title : Insulin increases de novo steroidogenesis in prostate cancer cells Running title : Insulin increases steroidogenesis in prostate cancer cells

  2011cites this paper
• Management of side effects of androgen deprivation therapy.

  2011cites this paper
• Urological aspects of the metabolic syndrome

  2011cites this paper
• Insulin increases de novo steroidogenesis in prostate cancer cells.

  2011cites this paper
• Low Testosterone Associated With Obesity and the Metabolic Syndrome Contributes to Sexual Dysfunction and Cardiovascular Disease Risk in Men With Type 2 Diabetes

  2011cites this paper
• [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].

  2011cites this paper
• Incomplete Testosterone Suppression in Prostate Cancer

  2010cites this paper
• Incomplete testosterone suppression in prostate cancer.

  2010cites this paper
• Accountability measures to promote quality improvement.

  2010cites this paper